NDA 018692 · Hospira
Marcaine
Bupivacaine Hydrochloride · Spinal
Last checked: Nov 19, 2026Latest source record: Sep 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
May 4, 1984
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,836
341 Phase 3, 228 recruiting
FAERS reports
4,689
2,689 serious, 313 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 23, 2026.
MARCAINE SPINAL is indicated for subarachnoid injection in adults for the production of subarachnoid block (spinal anesthesia). MARCAINE SPINAL is an amide-local anesthetic indicated in adults for subarachnoid injection for the production of subarachnoid block (spinal anesthesia). ( 1 )
Mechanism: Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 4, 1984 Original approval · Type 3 - New Dosage Form Review
1 products under this application
- MARCAINE · BUPIVACAINE HYDROCHLORIDE 0.75% · INJECTABLE, SPINAL · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Bupivacaine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Perioperative Multimodal Analgesia Protocol for Supratentorial CraniotomyPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT06406829 · 2,000 participants (planned) · Start Feb 9, 2026 · Primary completion Dec 31, 2026
Drug: Dexmedetomidine; Normal saline · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
- Perioperative Multimodal Analgesia for Supratentorial CraniotomyPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07441421 · 2,000 participants (planned) · Start Mar 9, 2026 · Primary completion Dec 31, 2027
Drug: Dexmedetomidine · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
Sites: Beijing, China
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis PainPivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT04504812 · 1,937 participants · Start Feb 1, 2021 · Primary completion Apr 8, 2025
Drug: Duloxetine · For: Knee Osteoarthritis
Sites: Sacramento, California; San Diego, California; Aurora, Colorado · 24 sites in all
- Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)Pivotal-lookingRecruiting
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06452147 · 1,860 participants (planned) · Start Jun 19, 2024 · Primary completion Jul 30, 2028
Drug: Bupivacaine liposome; Regular local anesthetic and 1 more · For: Anesthesia; Hip Fractures; Dementia and 2 more
Sites: Dongyang, China; Hangzhou, China; Jinhua, China · 13 sites in all
- Catheter Outcomes With Sternotomy Cardiac OperatedPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01648777 · 1,502 participants · Start Mar 2012 · Primary completion Jan 2015
Drug: placebo · For: Pneumonia; Cardiac Surgery; Multiperforated Catheter and 2 more
Sites: Paris, France
- Efficacy and Safety of Intrathecal Morphine for Postoperative Pain Management Following Planned Caesarean SectionPivotal-lookingRecruiting
Anne Juul WikkelsøAcademic, hospital or other
NCT06797973 · 1,312 participants (planned) · Start Jul 15, 2025 · Primary completion May 31, 2027
Drug: Intrathecal Morphine; Placebo (Sodium Chloride Injection, 0.9%) · For: Caesarean Section; Postoperative Pain
Sites: Aarhus, Denmark; Copenhagen, Denmark; Herlev, Denmark · 9 sites in all
- Combined Spinal-epidural Anesthesia for Cesarean Section Without Prophylactical Prehydration and VasopressorsPivotal-lookingStatus unknown
Shenzhen People's HospitalAcademic, hospital or other
NCT03497364 · 930 participants (planned) · Start May 1, 2018 · Primary completion Nov 30, 2021
Drug: bupivacaine; ropivacaine · For: Cesarean Section; Anesthesia, Spinal
Sites: Shenzhen, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,616
- anaesthetic complication283
- off label use246
- pain219
- hypoaesthesia209
- maternal exposure during pregnancy209
- hypotension199
- headache177
- dyspnoea168
- dizziness154
- nausea145
- condition aggravated143
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 91 |
| 2005 | 77 |
| 2006 | 97 |
| 2007 | 65 |
| 2008 | 80 |
| 2009 | 115 |
| 2010 | 86 |
| 2011 | 100 |
| 2012 | 92 |
| 2013 | 98 |
| 2014 | 122 |
| 2015 | 191 |
| 2016 | 617 |
| 2017 | 385 |
| 2018 | 244 |
| 2019 | 240 |
| 2020 | 239 |
| 2021 | 194 |
| 2022 | 401 |
| 2023 | 251 |
| 2024 | 325 |
| 2025 | 333 |
| 2026 | 246 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 9, 2026
Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62).
Current · updated Nov 9, 2026
Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10). Other
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Marcaine (Bupivacaine HCl)
2024 spending
$262
Beneficiaries
16
18 claims
Per beneficiary
$16
$0.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $382 |
| 2022 | $0 |
| 2023 | $297 |
| 2024 | $262 |
Part D: Marcaine (Bupivacaine HCl/PF)
2024 spending
$302
Beneficiaries
24
30 claims
Per beneficiary
$13
$0.53 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $263 |
| 2022 | $161 |
| 2023 | $694 |
| 2024 | $302 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Analgesic Effectiveness of Liposomal Bupivacaine versus Plain Local Anesthetics for Abdominal Fascial Plane Blocks: A Systematic Review and Meta-analysis of Randomized Trials.
Hussain N, Speer J, Abdallah FW · Anesthesiology 2024 · Meta-Analysis, Systematic Review
- Liposomal Bupivacaine, Plain Bupivacaine, and Saline for Transversus Abdominis Plane Blocks: The CLEVELAND Randomized Trial.
Turan A, Ali Sakr Esa W, Brooker J, et al. · Anesthesiology 2026 · Randomized Controlled Trial
- Addition of Liposomal Bupivacaine to Standard Bupivacaine versus Standard Bupivacaine Alone in the Supraclavicular Brachial Plexus Block: A Randomized Controlled Trial.
Chan TCW, Wong JSH, Wang F, et al. · Anesthesiology 2024 · Randomized Controlled Trial, Comparative Study
- Liposomal bupivacaine peripheral nerve block for the management of postoperative pain.
Hamilton TW, Athanassoglou V, Trivella M, et al. · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Combined pectoralis and serratus anterior plane blocks with or without liposomal bupivacaine for minimally invasive thoracic surgery: A randomized clinical trial.
Marciniak D, Raymond D, Alfirevic A, et al. · J Clin Anesth 2024 · Randomized Controlled Trial
- Spinal anesthesia: bupivacaine compared with tetracaine.
Moore DC · Anesth Analg 1980 · Clinical Trial, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.